Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
17β-Hydroxysteroid dehydrogenase (17β-HSD) inhibitors in this category mostly target one aldo-keto reductase. Aldo-keto reductase family 1 member C3 (AKR1C3), also called type 5 17β-HSD, reduces androstenedione to testosterone in peripheral tissues. Its close relatives AKR1C1 and AKR1C2 act mainly on other steroids, inactivating progesterone and 5α-dihydrotestosterone. These isoforms share high sequence identity, so selectivity between them is a central question in inhibitor research. AKR1C3-IN-1 and AKR1C2/3-IN-1 address AKR1C3, while AKR1C1-IN-1 is directed at AKR1C1. Stylopine, a protoberberine alkaloid, is also listed as an AKR1C3 inhibitor. AKR1B10-IN-1 targets AKR1B10, a reductase of a neighboring subfamily that is studied in retinoid and lipid metabolism.
HSD17B13-IN-76 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research into liver diseases and metabolic disorders, facilitating studies on the biochemical pathways regulated by HSD17B13 and its role in steroid metabolism.
Out of stock
All 3 sizes
BMS-856 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3). It demonstrates potent inhibitory activity with IC50 values of 60 nM in enzyme assays and 300 nM in whole cell assays, effectively disrupting the enzyme's activity. BMS-856 is valuable for research focused on steroidogenesis and potential therapeutic applications in hormonal disorders, particularly those related to testosterone metabolism.
HSD17B13-IN-74 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool in the study of liver diseases and metabolic disorders, enabling the exploration of HSD17B13's role in steroid metabolism. Its potent inhibition can facilitate research into therapeutic strategies targeting related pathologies.
Out of stock
All 3 sizes
HSD17B13-IN-86 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its ability to modulate HSD17B13 activity makes it a useful tool in the exploration of therapeutic strategies for these conditions.
Out of stock
All 3 sizes
HSD17B13-IN-52 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver conditions, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies related to drug-induced liver injury (DILI).
Out of stock
All 3 sizes
HSD17B13-IN-103 is a selective inhibitor of the enzyme HSD17B13. This compound demonstrates potential in research focused on non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Its inhibition of HSD17B13 may provide insights into therapeutic strategies for metabolic liver diseases.
Out of stock
All 3 sizes
Synonyms: STX1383
SCH-451659 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) with an IC50 of 2.4 nM. By blocking the conversion of androstenedione to testosterone, SCH-451659 effectively lowers testosterone levels in vivo. This compound exhibits potential anticancer activity, particularly against prostate tumors that depend on androstenedione. Its specific targeting mechanism makes SCH-451659 a valuable reagent for research in hormone-related cancer therapies.
HSD17B13-IN-62 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver diseases (NAFLD), providing valuable insights into the mechanisms of lipid metabolism and hormone regulation. Its application may aid in the development of therapeutic strategies targeting liver dysfunction and associated metabolic disorders.
Out of stock
All 3 sizes
HSD17B13-IN-17 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of less than 0.1 μM for estradiol and under 1 μM for Leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-17 is essential for research focused on the modulation of lipid metabolism and the therapeutic potential of HSD17B13 inhibitors in liver-related disorders.
Out of stock
All 3 sizes
HSD17B13-IN-66 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for researching liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a promising tool for elucidating the role of HSD17B13 in various pathophysiological processes.
Out of stock
All 3 sizes
HSD17B13-IN-65 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted action on HSD17B13 allows for the exploration of therapeutic strategies in these areas.
Out of stock
All 3 sizes
HSD17B13-IN-27 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is instrumental in research involving nonalcoholic fatty liver diseases (NAFLD), including nonalcoholic steatohepatitis (NASH). Its ability to modulate steroid hormone metabolism positions it as a valuable tool for studying metabolic disorders and developing therapeutic strategies.
Out of stock
All 3 sizes
HSD17B13-IN-13 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver pathologies, including non-alcoholic fatty liver disease (NAFLD). Its potent inhibitory activity makes it a useful tool for elucidating the biochemical mechanisms underlying liver disorders and developing therapeutic strategies.
Out of stock
All 3 sizes
HSD17B13-IN-19 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its inhibition of HSD17B13 may provide insights into therapeutic strategies for managing liver-related metabolic disorders.
Out of stock
All 3 sizes
HSD17B13-IN-80-d3 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and may serve as a valuable tool for studying metabolic regulation and liver-related pathologies.
Out of stock
All 3 sizes
HSD17B13-IN-75 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-75 can be utilized in studies focused on drug-induced liver injury (DILI).
Out of stock
All 3 sizes
HSD17B13-IN-46 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases and metabolic disorders, providing valuable insights into the modulation of steroid hormone regulation and related pathophysiologies. Its high specificity and efficacy make it a significant tool for further investigations in these areas.
Out of stock
All 3 sizes
HSD17B13-IN-32 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound demonstrates significant potential for research applications in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition may facilitate the investigation of HSD17B13's role in these pathologies.
Out of stock
All 3 sizes
EM 1404 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) with an IC50 of 3.2 nM. This compound plays a crucial role in modulating androgen metabolism and has significant implications in the study of hormone-related disorders. EM 1404 is valuable for research focused on exploring therapeutic strategies for conditions associated with altered steroid hormone levels.
HSD17B13-IN-39 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), a key enzyme implicated in lipid metabolism and liver function. This compound is particularly relevant for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. HSD17B13-IN-39 provides essential insights into the role of HSD17B13 in disease mechanisms and potential therapeutic interventions.
HSD17B13-IN-1 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM with estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-1 provides valuable insights into the biochemical pathways involved in fatty liver disease and serves as a potential therapeutic target for related conditions.
Out of stock
All 3 sizes
HSD17B13-IN-31 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is crucial in researching nonalcoholic fatty liver diseases (NAFLDs), particularly nonalcoholic steatohepatitis (NASH), by modulating lipid metabolism and inflammation. HSD17B13-IN-31 serves as a valuable tool for studying the role of HSD17B13 in liver-related disorders and therapeutic interventions.
Out of stock
All 3 sizes
CRT0083914 is a selective non-carboxylate inhibitor of the enzyme AKR1C3. This compound exhibits significant biological activity against AKR1C3, making it a valuable tool for studying its role in colon cancer. Researchers can utilize CRT0083914 to explore its potential therapeutic effects and mechanistic insights in the context of cancer research.
HSD17B13-IN-42 targets hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) as a potent inhibitor, exhibiting an IC50 of less than 0.1 μM with estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it a valuable tool for researchers investigating metabolic disorders and liver pathologies.
Out of stock
All 3 sizes
HSD17B13-IN-37 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is utilized in research focused on nonalcoholic fatty liver disease (NAFLD), where it aids in elucidating the role of HSD17B13 in lipid metabolism and liver pathophysiology. Its potent inhibitory activity makes it a valuable tool for investigating therapeutic strategies targeting HSD17B13-related pathways.
Out of stock
All 3 sizes